Exhibit 99.1

Market Update April 11, 2024

Advanced Health Intelligence grants extension to Changlin Network Technology Ltd Exclusive License Completion

Highlights

Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) (“AHI” or the “Company”) wishes to inform shareholders that the Company has granted an extension to 30 June 2024 for the previously executed binding exclusive, perpetual license with Shanghai-based Changlin Network Technology Ltd (Changlin).

Changlin has continued to share advanced discussions with AHI regarding completing the Changlin funding program. Changlin is making progress towards acquiring the capital required under the agreement. In addition, Changlin has continued to advance commercial partnership discussions with some of China’s most prominent insurers and healthcare organisations. While we cannot disclose the specific names of these entities, the significance of these collaborations cannot be understated. The depth and potential of these partnerships have greatly strengthened AHI’s confidence in Changlin’s endeavours. With this shared detail, AHI has granted the requested extension period.

On August 4, 2023, AHI informed shareholders that the Company had executed a binding exclusive, perpetual license with Shanghai-based Changlin.

Changlin and AHI worked together to conclude the terms and commercial aspects of the exclusive license for China. On August 4th, we were pleased to inform shareholders of the conclusion and signing of the license between the groups, subject only to Changlin’s payment of the USD$10 million license fee.

The collaboration between AHI and Changlin signifies a transformative leap into the future of healthcare in China - a future that seamlessly blends cutting-edge technology with unparalleled accessibility. As frontrunners in this healthcare revolution, we are committed to proving that impactful innovation can also be cost-effective.

Our strategy to embed health screening functionalities into everyday devices unlocks a powerful, proprietary solution that is exceptionally scalable for preventative healthcare, especially within populous countries like China. This convergence of accessibility, convenience, and state-of-the-art technology ensures Changlin’s approach stands apart, effectively pioneering the trajectory of future healthcare developments.

Chronic diseases have become a prominent public health concern in China, with increasing prevalence due to changing lifestyles and an aging population. Conditions such as diabetes, hypertension, and cardiovascular diseases significantly burden the healthcare system, primarily due to late-stage identification leading to episodic, event-driven care that can be both costly and less effective.

Market Update April 11, 2024

Changlin recognises that the need for early identification and intervention of these chronic conditions is crucial. It not only aids in mitigating the progression of the disease but also drastically reduces the health and economic burden. Changlin believes the adoption of the AHI technology will drive proactive health management strategies, using the predictive analytics capabilities of the AHI biometric health assessment and personalising care on an individualised basis.

This innovation will help China shift from an event-driven healthcare paradigm to a preventive one. This shift will enable patients to receive timely care, resulting in better health outcomes and more efficient utilisation of healthcare resources.

Integrating AHI’s cutting-edge health screening capabilities within mobile phone technology brings accessibility, convenience, and population screening more adaptable than ever. This convenience is especially crucial when considering the sheer scale of China’s population. With 1.4 billion people, the ability to access health screening via something as ubiquitous as a mobile phone is not just beneficial but transformative. It allows the technology to be easily scaled, extending its reach to the country’s remotest corners. This universal accessibility positions AHI’s technology as a powerful tool in managing and preventing chronic disease, especially amongst the most vulnerable demographics.

Commercial benefit will only be realised once the initial licence payment is received and commercialisation commences and AHI receives the outlined revenue share. Additional commercial benefits will be the annual USD$5m license fee. Importantly, the above financial impact on AHI can only be realised once the initial license fee is paid.

Vlado Bosanac, Founder and Head of Strategy at AHI, said:

“AHI acknowledges the delays Changlin has encountered, partly due to our own trading suspension, which coincided with Changlin’s funding closure timeline. We appreciate Changlin’s dedication to the mutual commercial benefits our partnership promises. As AHI prepares to resume trading and showcase our commercial progress, we believe this will further bolster the representation and effectiveness of our joint endeavours.

Considering this, AHI is extending its timeframe with Changlin, acknowledging the substantial financial and commercial progress they have achieved within China’s complex market. With its extensive population and burgeoning healthcare needs, China presents both immense potential and distinctive challenges.

Changlin, with its local expertise and industry knowledge, remains an essential ally for AHI in navigating this market. This alliance solidified through an exclusive licensing agreement, helps surmount various operational hurdles and mitigates concerns within Chinese jurisdictions.

China’s rapid economic ascent, urbanisation, and demographic shifts have led to an uptick in chronic conditions like heart disease, stroke, cancer, diabetes, and respiratory ailments. In this context, AHI’s innovative technology becomes particularly crucial. Our capabilities in detecting chronic disease risks align with the country’s health imperatives.

Our continued collaboration with Changlin is a testament to our collective intent to harness technology for better health outcomes. By aligning our strategic goals, we are setting a course to deliver substantial value to our respective companies, shareholders, and the wider Chinese community.”

About Changlin Network Technology Co LTD

Established in 2018, Changlin Network Technology Ltd was founded to deliver cost-effective, convenient healthcare and screening services to the Chinese population. The organisation was founded by industry experts Russell Bateman and Cecilia Qiao, bringing decades of global experience in the insurance and healthcare sectors, including regions such as China, UAE, Saudi Arabia, Australia, Hong Kong, and Europe.

With a deep understanding of international healthcare systems and the insurance industry, Bateman and Qiao have worked closely with governments and some of the world’s largest insurers and reinsurers, bringing together knowledge across industry requirements, governments’ needs and the ability to identify and execute required objective to create Changlin, a company specifically designed to address China’s healthcare needs.

Leveraging the knowledge they gathered when working with the government-owned China Pacific Insurance Company (CPIC) with over 171m policyholders, Qiao and Bateman were at the epicentre of the Chinese Government’s 2030 Health Initiative. With this understanding, Changlin has developed a unique solution architecture by identifying and acquiring license agreements for ground-breaking technologies, aiming to bring digital health screening to China’s vast population of 1.4 billion people.

Market Update April 11, 2024

Changlin’s primary focus is on providing solutions that can transform and enhance healthcare in China, addressing the need for mass screening whilst reducing the existing cost concerns in the heavily burdened Chinese healthcare system. Changlin’s emphasis is addressing chronic diseases, recognising the necessity for early detection, prompt treatment, and long-term sustainable care.

By working closely with insurers, reinsurers, healthcare organisations, and the Chinese government, Changlin is committed to delivering solutions that will create a lasting positive economic impact across China, spearheading the transformation of the ongoing evolution of digital healthcare.

For more information, contact: 

The Chairman and CEO of Advanced Health Intelligence Ltd have approved this announcement.

About Advanced Health Intelligence Ltd

Advanced Health Intelligence Ltd (AHI) is committed to becoming a global leader in digital health, harnessing its proprietary technology and innovative processes to redefine health screening. Leveraging smartphones’ ubiquity and convenience, AHI aims to deliver a comprehensive suite of assessment tools to healthcare providers, caregivers, insurers, and governments around the world.

Our mission is to improve healthcare outcomes, enhance health literacy, and support the early detection and management of various health conditions.

Since our inception in 2014, AHI has been at the forefront of Health-tech innovation, starting with the world’s first on-device body dimensioning capability. Our patented technology has evolved into a robust suite of solutions symbolising digitised healthcare’s future.

Our key offerings include:

At the heart of AHI is our world-class team comprising machine learning and AI experts, computer vision specialists, and medically trained data scientists. Their collective expertise ensures AHI remains at the cutting edge of health-tech innovation, tailoring our technology to meet the evolving needs of our consumers.

AHI’s vision extends beyond individual health assessments. We aspire to create a transformative impact at scale, driving a new digital healthcare era. Our biometrically derived triage solution, accessible via a smartphone, enables our partners to identify and manage health risks at a population scale.

In the pursuit of proactive health management, AHI stands ready to guide healthcare providers, caregivers, insurers, and governments in triaging individuals into the most suitable care pathways. Through technology, AHI is contributing to a more efficient, effective, and inclusive global healthcare system.

For more information, please visit:  www.ahi.tech

Exhibit 99.2

Market Update April 15, 2024

UAE-based E-Script medicine management company Pharmak Direct and AHI Extend Master Services Agreement

Highlights

Advanced Health Intelligence Ltd (ASX/NASDAQ:AHI) (“AHI” or “the Company”) is pleased to inform shareholders that the Company has extended the previously executed Master Services Agreement (“MSA”) with Pharmak Direct, allowing the parties additional time to integrate the solutions, as set out in the terms and conditions of the MSA between AHI and Pharmak Direct. All other terms and conditions have remained the same, and the parties will work together over the 90-day extension to conclude integration and release in accordance with the previously executed MSA.

As previously disclosed, Dubai-based Pharmak Direct is a prominent stakeholder in the Middle Eastern e-script market, providing innovative digital home and workplace prescription delivery solutions. The company offers a comprehensive platform that enables payers, doctors, and patients to manage prescriptions and delivery.

Pharmak represents a transformative shift in the prescription landscape with its e-script dispensing and packaging system (ESPS), enabling the company’s unique 8-minute e-script-to-packaged capability. By leveraging technology to digitise and streamline the end-to-end prescription process, Pharmak Direct enhances efficiency, accuracy, and patient safety, ultimately improving the overall healthcare experience.

Under the terms of the MSA, with the assistance of AHI, Pharmak will integrate the AHI Biometric Health Assessment capabilities, enhancing the e-script patient experience and facilitating cost-effective medication and health management solutions with the Pharmak Direct ESPS. Once integrated, Pharmak is committed to delivering the e-script and screening solution to all current and future Pharmak partners. This is intended to seamlessly provide health data directly into the joint AHI / Pharmak ESPS, further providing Health insurers, government, and healthcare professionals with valuable insights into the patient’s overall health status.

Pharmak partners utilising the transformative e-script screening solution will experience the remarkable advantages of enriched patient data, which will be made possible by integrating AHI technology. The AHI capability is seamlessly incorporated within the comprehensive e-script package at no additional cost to the Pharmak valued partners.

The collaboration between Pharmak and AHI introduces a pioneering approach to medication management in the MENA region by incorporating biometric assessments into the e-scripting process. This integration aims to leverage individual biometric data to enhance care and medication management precision. It signifies a strategic shift towards more personalised healthcare, enabling care providers to deliver tailored therapeutic outcomes through advanced biometric technology. This initiative responds to the evolving role of care providers working to address the need for comprehensive evaluation of pharmaceutical care’s clinical, economic, and humanistic impacts. Embracing such innovation is crucial for managing the region’s high chronic disease prevalence and improving overall healthcare outcomes.

AHI and Pharmak believe the pharmacy should play a crucial role in the early detection of chronic diseases and in providing prevention capabilities, assisting in managing diseases, and counselling to improve patients’ quality of life and medication adherence. Studies have shown that pharmaceutical care services can reduce hospitalisation rates and mortality, affect drug therapy costs, and highlight the importance of pharmacoeconomic evaluation.

Market Update April 15, 2024

Patient satisfaction with pharmaceutical care services is vital, and pharmacists face challenges like time constraints and access to patient medical information.

While focused on patient safety and effectiveness, the MENA region’s medication management landscape faces fragmentation with too many systems that must interact more effectively, hindering optimal health outcomes. AHI addresses this gap by developing an enterprise platform to consolidate these disparate elements into a unified, outcome-driven care model.

The AHI Enterprise Care Platform is positioned to revolutionise healthcare management by introducing interoperability across multiple critical domains, risk assessment screening, telehealth, e-scripting, medication management, Pharmaceutical Benefit Management, phenotypical profiling, and epidemiological predictive screening at a population scale.

Designed to streamline the complexity of contemporary medication management, this platform will seamlessly merge pharmaceutical care with multifaceted evaluations, ensuring that Clinical Services are both comprehensive and sustainable. This transformative approach is set to deliver integrated, patient-centred care throughout the MENA region, responding adeptly to the urgent needs arising from the high prevalence of chronic diseases.

The partnership comes at a time when the MENA region is extremely vocal about investing heavily in the digitisation of healthcare and population screening. In Saudi alone, the Kingdom has allocated USD$50.3 billion to healthcare and social development.i Much of this budget is directed toward digital health initiatives to enhance accessibility, efficiency, and transparency within the healthcare system.

Among these initiatives was creating a unified national electronic health record system, which acts as a comprehensive database to ensure patient data is accessible to medical professionals nationwide, enabling seamless cooperation and swift decision-making.

AHI’s BHA delivers 61 outputs, with 41 biometrics, across 5 health categories so patients can better understand their well-being and proactively address any concerns. The phenotypical data derived from the AHI BHA is unparalleled in the market.

Further investment in telemedicine platforms is prioritised, ensuring healthcare access even in remote areas.ii

Under Vision 2030, the Saudi government has also been working toward privatising the healthcare industry, focusing on 290 government hospitals and 2,300 primary health centres in the Kingdom.iii

AHI – Enterprise Care Platform

Market Update April 15, 2024

Vlado Bosanac, Head of Strategy at AHI, said:

“AHI is continuing to expand its operations in the MENA region, with a strong emphasis on strategic initiatives within the UAE that support local healthcare goals. Our approach, focusing on enhancing patient care by raising health risk awareness and integrating with local medication management systems, particularly for at-risk populations, is underscored by the valuable relationships we’ve established.

We appreciate the Pharmak team’s patience and understanding as we navigate AHI’s reinstatement to the ASX and NASDAQ. This period has been an opportunity to strengthen our bonds and lay the groundwork for collaborative success.

Through the esteemed support of our local partner and significant shareholder, His Excellency Dr. Obaid Al Ketbi, AHI has fostered new relationships throughout the UAE. His Excellency’s influence and network have been instrumental in facilitating connections that amplify our impact in the region.

In active discussions with insurers, government entities, and care networks, we’re advancing the integration of our proprietary screening technology into e-prescription systems. This key development is a welcome addition to our mission of transforming health risk management, offering easy access to biometric data for personalised patient care.

Over the last 10 months, AHI has solidified its position in the MENA region, progressing with initiatives to improve the digitisation of risk identification in healthcare; electronic prescription systems are just one of the initiatives we are executing.

This is a key strategic move by Pharmak, who we believe is the leading electronic prescription provider in the UAE. The extension of the integration period within the signed Master Service Agreement (MSA) with AHI is to provide time lost throughout the delays AHI has had with its reinstatement.

By Pharmak choosing to integrate biometric health screenings into its process, Pharmak is poised to further cement its status as a leader in digital healthcare and medication management solutions throughout the region. This collaboration is a significant step in preventive healthcare wastage, empowering earlier detection and proactive management of health issues, which is pivotal in enhancing patient outcomes and reducing health risks through proactive population screening. “

About Pharmak Direct

Pharmak Direct is a user-friendly interface that simplifies the prescription packing and delivery workflow. Doctors submit electronic prescriptions directly to the Health Authority Pharmacy Benefit Management (PBM) portal after consultation with the patient. The patient then sends the e-script number directly to Pharmak Direct, eliminating the need for paper-based prescriptions and reducing the risk of errors. This streamlined process saves time and enhances patient safety by minimising the possibility of misinterpretation or lost prescriptions.

Furthermore, Pharmak Direct has been selected as the partner of choice by health insurers providing healthcare coverage for government health agencies in the United Arab Emirates and Saudi Arabia, allowing them to receive e-scripts, process orders, and dispense medication to patients efficiently. Pharmak receives all script details digitally, ensuring accurate dispensing and reducing the chance of medication errors. This digital integration fosters better collaboration between healthcare providers, improving patient care, adherence to medication consumption plans, and retention.

Pharmak Direct’s impact extends beyond the prescription process itself. The platform offers features such as medication reminders, drug interaction alerts, and digital health records, empowering patients to manage their health actively. Patients can stay informed and compliant with their treatment plans with convenient access to their prescription history and medication information.

Market Update April 15, 2024

The Chairman and CEO of Advanced Health Intelligence Ltd have approved this announcement.

For more information, contact:

About Advanced Health Intelligence Ltd

Advanced Health Intelligence Ltd (‘AHI’) delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes. 

Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world’s first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:  

Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI’s technology is at the forefront of innovation and the needs of our consumers. 

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale. 

For more information, please visit:  www.ahi.tech

Exhibit 99.3

ASX/NASDAQ Announcement 15 April 2024

AHI COMMENCES PLACEMENT TO RAISE AUD$1,957,500 (BEFORE COSTS) AS PART OF BROADER AUD$15,000,000 FUNDING PACKAGE

Highlights

Advanced Health Intelligence Ltd (ASX/NASDAQ: AHI) (AHI or the Company) is pleased to inform shareholders today that it has completed the first stage of its funding strategy. This will strengthen the Company’s balance sheet as it expands its reach and distribution across Asia, the Middle East, and North Africa (MENA) regions.

While this update presents wide-ranging funding offers and structures, we want to assure our shareholders that AHI’s intention is to move forward with funding that aligns with their best interests and the company’s need for adequate capital to meet AHI’s compliance, expansion and commercial endeavours.

These fund raisings are also expected to address the shareholder equity notification that AHI initially received from Nasdaq on 8 November 2023, which related to Company not being in compliance with the Nasdaq Listing Rule to maintain a minimum of USD$2,500,000 in net shareholders’ equity.

Oakley Capital Engagement and AUD$5.95 million funding

AHI is pleased to provide an update on the successful execution of its strategic capital-raising initiatives designed to fuel the Company's growth phase. This funding strategy, structured with Sydney-based Oakley Capital Partners Pty Ltd (Oakley Capital) in two initial parts, ensures a robust financial foundation for our continued expansion and innovation.

Part 1: Share Placement

The Company is pleased to inform shareholders that it has, by way of a private placement to sophisticated and professional investors, agreed to issue investors 29,000,000 fully paid ordinary shares (Shares) at A$0.0675 per Share together with 14,500,000 free attaching options to acquire Shares (Options) with an exercise price of A$0.10 each to be exercised within 3 years, raising AUD$1,957,500 (before costs) (Placement). Settlement of the Placement is subject to and conditional on the Company’s securities being reinstated to trading on ASX.

The issue of these Options is subject to shareholder approval under ASX Listing Rule 7.1 at a general meeting of shareholders that is expected to be held this May (May General Meeting).

ASX/NASDAQ Announcement 15 April 2024

AHI will use the net proceeds received from the Placement primarily for the Company’s current expansion into the MENA region, continued expansion across Asia, development of the Company’s product offerings, and business development and marketing, with the remainder of the proceeds to be used for general corporate purposes, including, without limitation, investing in or acquiring companies that are complementary to AHI’s existing business.

Oakley Capital is acting as the lead manager for the Placement. Oakley Capital will receive a cash fee of 6% of the gross proceeds of the Placement, plus 1,000,000 Shares and 5,000,000 Options at an exercise price of A$0.10 cents to expire three years from the issue date (on the same terms as the attaching Options to be issued to Placement participants). The issue of these Shares and Options is subject to shareholder approval under ASX Listing Rule 7.1 at the May General Meeting.

The material terms and conditions of the Options that are to be issued to the Placement participants and to Oakley Capital are annexed to this announcement.

Settlement of the issue of the 29,000,000 Shares is anticipated to occur on the Company’s reinstatement to trading on the ASX (refer below for an update on this), with the Placement Shares to be issued under the Company’s existing placement capacity under ASX Listing Rules 7.1 and 7.1A as follows:

AHI intends to seek to refresh its available placement capacity under ASX Listing Rules 7.1 and 7.1A at the May General Meeting.

Further information with respect to the Placement is set out in the Appendix 3B, which accompanies this announcement.

Part 2: Obsidian Convertible Note Facility

In our second phase, Oakley Capital has secured a Convertible Note facility for AHI with Obsidian Global Partners (Obsidian) to raise up to AUD$4 million.

Obsidian is a New York City-based alternative investment management firm focused on providing growth-oriented capital to public and private companies globally. Oakley Capital introduced Obsidian to AHI under its capital raising mandate with AHI.

Subject to:

AHI will draw down AUD$1.25 million from this facility, leaving a balance of AUD$2.75 million available for future drawdowns at the Company’s discretion.

AHI’s ability to make the initial and any future draw downs is subject to obtaining shareholder approval, the Company will accordingly seek approval under ASX Listing Rule 7.1 to draw down up to AUD$4 million under this facility at the May General Meeting. The term of this facility is 18 months from the initial drawdown, offering AHI flexibility in timing and financial planning.

ASX/NASDAQ Announcement 15 April 2024

The key terms of this Convertible Note facility with Obsidian are set out below:

ASX/NASDAQ Announcement 15 April 2024

AHI intends to use the net proceeds received from the issue of these Convertible Notes primarily for the Company’s current expansion into the MENA region, continued expansion and development of the Company’s business development and marketing, with the remainder of the proceeds to be used for general corporate purposes, including, without limitation, investing in or acquiring companies that are complementary to AHI’s existing business.

The Company has obtained legal advice from Steinepreis Paganin that none of the features noted in section 5.9 of Guidance Note 21 are present and that the terms of these Convertible Notes are market-standard, as there are other convertible notes on substantially similar terms in the marketplace.

The Company has engaged Oakley Capital for 12 months. The fees payable in relation to this engagement are set out above. Oakley Capital will continue to address capital-raising opportunities for the Company in Australia when and if required.

As noted above, AHI will seek approval under ASX Listing Rule 7.1 at the May General Meeting to issue up to A$4m worth of Convertible Notes under this Convertible Note facility with Obsidian. To the extent that less than AUD$4m worth of convertible notes are issued to Obsidian within three months of the May Geneal Meeting, AHI may seek a fresh shareholder approval to issue these notes, and may not issue any further notes until it has done so.

USD$5m Convertible Note

In addition to the funding arrangements described above, the Company will seek to place up to USD$5,000,000 in convertible notes to sophisticated investors (the “Convertible Notes”). This Convertible Notes offering is potentially in addition to the Obsidian convertible notes facility referred to above.

The key terms of this Convertible Notes facility are set out below:

ASX/NASDAQ Announcement 15 April 2024

The proceeds received from these Convertible Notes will be applied toward the Company’s working capital requirements and further expansion throughout the MENA region. The issue of these convertible notes is subject to AHI obtaining shareholder approval under ASX Listing Rule 7.1 at the May General Meeting. To the extent that less than USD$5m worth of convertible notes are issued under this facility within three months of the May General Meeting, AHI may seek a fresh shareholder approval to issue these notes, but may not issue any further notes under the facility until it has done so.

The Company has obtained legal advice from Steinepreis Paganin that none of the features noted in section 5.9 of Guidance Note 21 are present and that the terms of the Convertible Notes are market-standard, based on the reasons set out below:

The USD$5m convertible note raising that was described in AHI’s most recent quarterly report is not proceeding and will be replaced by the placement of convertible notes that is described above.

Further information with respect to the funding packages that are summarised above, please refer to the accompanying Appendix 3B’s.

R&D advance

AHI also intends to obtain an advance on its FY2024 R&D grant. The proposed terms of the advance are set out below. AHI is currently in advanced discussions with its existing research and development (R&D) funding organisation to secure up to A$1.5 million in advancement. This anticipated funding is set against the R&D reimbursement AHI expects to receive in 2024 from the Australian Government's R&D Tax Incentive scheme. The basis for this advancement includes calculations on historical and anticipated expenditures by AHI on research and development activities.

A significant development in this context is AHI is in the process of concluding its FY2023 R&D advance with our R&D funding partner, Asymmetric. Following this, we will promptly conclude negotiations for the FY2024 funding advancement. It is our expectation to secure the FY2024 funds subsequent to the initial capital-raising activities outlined in this announcement, with the anticipation of receiving the new R&D advance by no later than June 2024.

AHI will update the market once the terms of the R&D grant advance are finalised, but it is expected that the grant will be provided on the following terms:

ASX/NASDAQ Announcement 15 April 2024

Use of funds

A table setting out the proposed use of the funds that are expected to be raised under the facilities and capital raisings this year are described above is set out in the below table.

These amounts assume that the maximum available amounts are placed/drawn.

Notes:

ASX/NASDAQ Announcement 15 April 2024

SEPA and Staged Advances

As previously disclosed in the December quarterly update, AHI has had discussions for a significant Share Equity Purchase Agreement valued at USD$10,000,000, alongside an aggregate of USD$2,600,000 in staged advances to AHI.

The particulars of this arrangement could not be agreed on terms acceptable to the parties, which led to the parties mutually agreeing to suspend discussions with respect to this funding arrangement.

AHI will continue to seek funding to meet our capital requirements and ensure the Company’s continued growth and success.

Reinstatement to trading update

AHI wishes to update its shareholders on the timing for the Company’s securities to be reinstated to trading on the ASX. Following the finalisation and release of AHI’s Half Year Report on the ASX, which is expected to occur on or about 16 April 2024, AHI will be in discussions with the ASX regarding reinstatement. Following reinstatement, the Company expects:

The timing of the above matters is subject to some factors that are outside of AHI’s control, including ASX exercising its discretion to reinstate the Company’s securities to quotation. AHI is in discussions with ASX with respect to reinstatement, which may involve AHI being required to satisfy conditions imposed by ASX. These conditions may include ASX being satisfied as to AHI’s financial condition and, notwithstanding the intended timing of the capital raisings that is set out above, AHI demonstrating that it has completed some of the capital raisings contemplated in this announcement prior to reinstatement.

The Chairman and CEO of Advanced Health Intelligence Ltd have approved this announcement.

For more information, contact:

ASX/NASDAQ Announcement 15 April 2024

About Advanced Health Intelligence Ltd 

Advanced Health Intelligence (AHI) delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes. 

Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:  

Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI’s technology is at the forefront of innovation and the needs of our consumers. 

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale. 

For more information, please visit: www.ahi.tech

ASX/NASDAQ Announcement 15 April 2024

Schedule 1 – Terms of the Options

Each Option entitles the holder to subscribe for one fully paid Ordinary Share upon exercise of the Option.

Subject to paragraph (i), the amount payable upon exercise of each Option will be AUD$0.10 (Exercise Price).

Each Option will expire at 5:00 pm (AWST) on the date that is three years from the date of issue (Expiry Date). An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.

The Options are exercisable at any time on or prior to the Expiry Date (Exercise Period).

The Options may be exercised during the Exercise Period by notice in writing to the Company in the manner specified on the Option certificate (Notice of Exercise) and payment of the Exercise Price for each Option being exercised in Australian currency by electronic funds transfer or other means of payment acceptable to the Company.

A Notice of Exercise is only effective on and from the later of the date of receipt of the Notice of Exercise and the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (Exercise Date).

Within five Business Days after the Exercise Date, the Company will:

If a notice delivered under (g)(ii) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.

ASX/NASDAQ Announcement 15 April 2024

Shares issued on exercise of the Options rank equally with the then issued shares of the Company.

If at any time the issued capital of the Company is reconstructed, all rights of an Optionholder are to be changed in a manner consistent with the Corporations Act and the ASX Listing Rules at the time of the reconstruction.

There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options without exercising the Options.

An Option does not confer the right to a change in Exercise Price or a change in the number of underlying securities over which the Option can be exercised.

The Options are transferable subject to any restriction or escrow arrangements imposed by ASX or under applicable Australian securities laws.